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Abstract
Background: Alzheimer's disease is the most common progressive neurodegenerative disease. In
recent years, numerous progresses in the discovery of novel Alzheimer's disease molecular
biomarkers in brain as well as in biological fluids have been made. Among them, those involving lipid
metabolism are emerging as potential candidates. In particular, an accumulation of neutral lipids was
recently found by us in skin fibroblasts from Alzheimer's disease patients. Therefore, with the aim
to assess whether peripheral alterations in cholesterol homeostasis might be relevant in
Alzheimer's disease development and progression, in the present study we analyzed lipid
metabolism in plasma and peripheral blood mononuclear cells from Alzheimer's disease patients
and from their first-degree relatives.
Methods: Blood samples were obtained from 93 patients with probable Alzheimer's disease and
from 91 of their first-degree relatives. As controls we utilized 57, cognitively normal, over-65 year-
old volunteers and 113 blood donors aged 21-66 years, respectively. Data are reported as mean ±
standard error. Statistical calculations were performed using the statistical analysis software Origin
8.0 version. Data analysis was done using the Student t-test and the Pearson test.
Results: Data reported here show high neutral lipid levels and increased ACAT-1 protein in about
85% of peripheral blood mononuclear cells freshly isolated (ex vivo) from patients with probable
sporadic Alzheimer's disease compared to about 7% of cognitively normal age-matched controls.
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A significant reduction in high density lipoprotein-cholesterol levels in plasma from Alzheimer's
disease blood samples was also observed. Additionally, correlation analyses reveal a negative
correlation between high density lipoprotein-cholesterol and cognitive capacity, as determined by
Mini Mental State Examination, as well as between high density lipoprotein-cholesterol and neutral
lipid accumulation. We observed great variability in the neutral lipid-peripheral blood mononuclear
cells data and in plasma lipid analysis of the subjects enrolled as Alzheimer's disease-first-degree
relatives. However, about 30% of them tend to display a peripheral metabolic cholesterol pattern
similar to that exhibited by Alzheimer's disease patients.
Conclusion: We suggest that neutral lipid-peripheral blood mononuclear cells and plasma high
density lipoprotein-cholesterol determinations might be of interest to outline a distinctive
metabolic profile applying to both Alzheimer's disease patients and asymptomatic subjects at higher
risk of disease.
Background
Alzheimer's disease (AD) is the most common progressive
neurodegenerative disease affecting millions of people
worldwide. The AD brain is marked by severe neurode-
generation like the loss of synapses and neurons, atrophy
and depletion of neurotransmitter systems in the hippoc-
ampus and cerebral cortex [1,2]. Although we still do not
know what starts the AD process, we do know that dam-
age to the brain begins as many as 10 to 20 years before
the symptoms. To date, AD diagnosis during life, and par-
ticularly of early stages of disease, is based on evaluation
of multiple parameters obtained through neuropsycho-
logical testing [3], conventional imaging [4] as well as the
exclusion of other neuropathologies by means of elabo-
rate, serial and expensive procedures. Numerous
progresses in the discovery, validation, and standardiza-
tion of molecular biomarkers in brain or biological fluids
of aid in diagnosis at different stages of AD and in the
assessment of disease progression, have recently been
made [5-7]. In particular, the analysis of amyloid beta-
peptides (Aβ) in the liquor and the advancements in func-
tional neuroimaging [8,9] have definitely improved the
accuracy of AD diagnosis; however, it is worth saying that
these procedures are available only in the best academic
centres and for a limited number of patients. On the con-
trary, in non-specialized hospital units there are several
problems to make accurate differential diagnosis of AD
over a large number of subjects and also assess whether a
mild cognitive impairment (MCI) might reveal early
stages of disease or should rather be linked to normal
aging. Therefore, a first-line test, even though not as spe-
cific as those mentioned above, yet easy to be performed
and denoting systemic metabolic alterations would be an
useful tool for basic and clinical AD research.
Recently, an interesting blood test for early AD diagnosis
based on the expression of eighteen signaling plasma pro-
teins was reported [10]. Waiting for the assay validation
by other research groups, these findings lend further sup-
port to the hypothesis that AD patients suffer from a sys-
temic metabolic dysfunction that beyond the brain affects
also other tissues including dermal fibroblasts, which
have often been employed as an in vitro model for neuro-
logical diseases, particularly AD [11,12]. Indeed, we have
recently reported that skin fibroblasts from patients with
diagnosis of probable sporadic AD display an imbalance
between free cholesterol (FC) and cholesterol esters (CEs)
pools to suggest that increased CE levels in these cells may
represent an additional peripheral indicator of disease
[13,14].
These metabolic alterations in dermal fibroblasts
prompted us to further investigate cholesterol metabo-
lism in freshly isolated (ex vivo) peripheral blood mono-
nuclear cells (PBMCs). These cells are an ideal source for
investigation due to their critical roles in immune
response, metabolism, and communication with other
cells and extracellular matrices almost everywhere in the
human body, as well as for their ease of collection [15].
Moreover, starting from the notion that family history of
AD-like dementia is considered a high-risk factor for the
development of this disease [16,17] and with the aim to
identify sensitive metabolic traits in support to diagnosis
of probable AD, we have analyzed lipid metabolism in
freshly isolated (ex vivo) PBMCs, and in plasma of AD
patients and of their cognitively normal first degree rela-
tives (AD-FDR).
As controls, we utilized cognitively normal over-65-year-
old subjects (control 1) and blood donors aged 21-66
years (control 2). High levels of neutral lipids (NL),
mainly CEs, in PBMCs and low high density lipoprotein-
cholesterol (HDL-C) levels in plasma have been found in
about 90% of patients with probable sporadic AD exam-
ined. As expected, a great variability in the NL-PBMCs data
and in plasma lipid analysis of the subjects enrolled as
AD-FDR was found; however, about 30% of them dis-
played a peripheral metabolic cholesterol pattern similar
to that of the AD patient in each one of their families.BMC Medicine 2009, 7:66 http://www.biomedcentral.com/1741-7015/7/66
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Methods
Participants
Blood samples were obtained from patients with possible
or probable AD and from their FDR (see data reported in
Table 1 and Table 2, respectively). Subjects were enrolled
at the Alzheimer Center, USL 8, Cagliari, and at the Geri-
atric Unit of the University Hospital, Cagliari (Italy) fol-
lowing informed written consent from all individuals or,
when necessary, from their legal guardians, under local
institutional review board supervision and with approval
by local Ethical Committees. Routine clinical and labora-
tory evaluation, including magnetic resonance imaging,
was performed to exclude other causes of cognitive
impairment. Patient evaluation included medical history,
physical and neurological examinations, and laboratory
blood tests to rule out metabolic causes of dementia (thy-
roid hormones, Vitamin B12, etc.), and neuroimaging
(computer tomography and/or magnetic resonance) of
the brain. In addition, all patients underwent neuropsy-
chological tests, including the clinical dementia rating
scale (CDR), the global deterioration scale (GDS), the
Clock Drawing Test (CDT) and the Mini-Mental State
Examination (MMSE) corrected for degree of schooling
and age. Patients had CDR score 3-5, GDS score 6-7, CDT
score < 12, and MMSE score < 24. Patients with neoplastic
or hematological disorders, recent infections, severe
hepatic or renal failure, myocardial infarction or cranial
trauma in the previous six months, or who had received
statins, antineoplastic, corticosteroid, or immunosuppres-
sive drug treatment or surgery were not included in the
present study. Additionally, 170 individuals: 57 volun-
teers (control 1) aged between 66-87 years, with no cogni-
tive impairment, as established by clinical interview and
by a normal CDR, GDS and MMSE score, and 113 blood
donors (control 2), enrolled at the Transfusion Center,
USL7, Iglesias, Italy, aged between 20-66 years (table 2),
with no personal or family history of neurological or psy-
chiatric disorders, served as controls. Given the influence
of malnutrition on cholesterol metabolism, either under-
or over-weight subjects have intentionally been excluded
from the present study.
Isolation of PBMCs
Blood samples were centrifuged at 2200 rpm for 15 min
to separate plasma. Plasma was removed, transferred to
centrifuge tubes and stored at -80°C until analysis. The
buffy coat was collected and peripheral blood mononu-
clear cells (PBMCs) were isolated by density gradient cen-
trifugation (Lymphoprep; density, 1.077 g/L; Nycomed
Pharma, Oslo, Norway) at 1200 rpm for 10 minutes at
20°C, and washed twice with Hanks balanced salt solu-
tion (HBSS). These freshly isolated (ex vivo) PBMCs were
utilized for the experiments. Where indicated, purified
PBMCs were seeded onto 24-well plates at 1.0 × 104/mL
in RPMI 1640 medium with the standard supplements:
(10% fetal calf serum (FCS), 200 mM L-glutamine, and
100 U/mL penicillin-streptomycin) and growth-stimu-
lated with 10 μg/ml phytohemagglutinin (PHA; Sigma)
for 24, 48 and 72 hours. The trypan blue exclusion test
was used to assess cell viability.
[3H]Thymidine-incorporation studies
At the time points considered, cells were incubated in trip-
licate for 6 h with [3H]thymidine (5 μCi/ml). After incu-
bation, the cells were rinsed twice with phosphate
buffered saline (PBS), and DNA was precipitated by add-
ing 5% trichloroacetic acid at 4°C. Cells were digested
with 1 M NaOH at room temperature. Aliquots were
assayed for [3H]thymidine radioactivity and protein con-
tent.
Cellular lipid synthesis and efflux
To determine the rate of lipid synthesis, PBMCs were incu-
bated for 6 h with 5 μCi/ml sodium [14C]acetate (DuPont
± NEN; specific radioactivity 50 mCi/mmol). At 6, 18 and
36 h of incubation, cells were harvested, washed with PBS,
and total lipids (TL) in cells and medium extracted with
cold acetone. Lipid subclasses (FC, CE and triglycerides
Table 1: Characteristics of control 1 subjects and Alzheimer's disease patients.
Control 1 AD
Total Female Male Total Female Male
Number 57 37 20 93 67 26
Age (mean ± SE) 77.2 ± 0.8 77.0 ± 1.0 77.5 ± 1.3 77.2 ± 0.7 77.9 ± 0.9 77.1 ± 1.3
t-test (C1 vs AD) P = 0.944 P = 0.534 P = 0.206
MMSE 28.2 ± 0.2 27.9 ± 1.3 28.6 ± 0.3 18.7 ± 0.6 18.9 ± 0.6 18.3 ± 1.3
t-test (C1 vs AD) P = 0.000 P = 0.000 P = 0.000
ORO (mean ± SE) 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 2.6 ± 0.1 2.7 ± 0.1 2.5 ± 0.2
t-test (C1 vs AD) P = 0.000 P = 0.000 P = 0.000
MMSE = Mini Mental State Examination
AD = Alzheimer's Disease
ORO = Oil Red OBMC Medicine 2009, 7:66 http://www.biomedcentral.com/1741-7015/7/66
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[TG]) were separated by thin layer chromatography (TLC
TLC on kiesegel plates (Merck, Darmstadt, Germany)
using a solvent system containing n-heptane/isopropyl
ether/formic acid (60:40: 2, by vol.) and the incorpora-
tion of [14C]acetate into these different lipid fractions in
cells and medium was measured in a Liquid Scintillation
Counter. Efflux of [14C]TL from the cells into the medium
at each time point was expressed as the percentage of the
radioactivity recovered in medium/total radioactivity
(cells + medium).
Plasma lipid profile
Total cholesterol (TC) and HDL-C content was deter-
mined in plasma by using routine colorimetric enzymatic
procedures (Sclavo Diagnostics International S.r.l. Sovi-
cille, Italy).
Neutral lipid staining
To visualize the degree of cytoplasmic neutral lipid accu-
mulation, freshly isolated PBMCs were washed three
times with PBS, and fixed by soaking in 10% formalin.
Cells were then treated with isopropyl alcohol (60%),
washed, and stained with oil red O (ORO) (a lipid-solu-
ble dye which stains NL, including CE, but not FC). They
appear as bright red spots in the cytoplasm, and are then
counterstained with Mayer's hematoxylin. After staining,
cells were imaged using a Leitz inverted-phase microscope
fitted with a digital camera. At least two different fields per
sample were imaged and analyzed. The red intensity was
scored on a semi-quantitative scale (from 0 to 4) by two
blinded observers: 0 indicated no staining; 1, rare positive
cells or staining barely visible at low power (×200); 2,
focal staining or faint diffuse staining clearly visible at low
power; 3, multifocal staining or moderate diffuse staining;
and 4, intense diffuse staining. There was significantly
high correlation between the scores of the two observers
(r2 = 0.96; P = 0.000). For convenience, scores from only
one observer were used for cell mean-score calculation. In
some experiments ORO intensity was determined using
Image J software (National Institutes of Health, United
States). Red intensity was expressed as mean pixels ± SE/
cm2 of triplicate wells and obtained by utilizing four dif-
ferent selected regions of interest (ROIs).
Statistical analysis
Data are reported as mean ± standard error (SE). Statistical
calculations were performed using the statistical analysis
software Origin 8.0 version (Microcal, Inc, Northampton,
MA, USA). Data analysis was done using the Student t-test
and the Pearson test. A value of P < 0.05 was considered
to be statistically significant.
Results
Lipid profiles in freshly isolated PBMCs from AD patients 
and elderly controls
Characteristics of 93 AD patients (mean age 77.2 ± 0.7, 67
female and 26 male) and 57 controls (mean age 77.2 ±
0.8, 37 female and 20 male) enrolled for this study are
given in Table 1.
We initially determined the content of NL in ex vivo
PBMCs from AD patients and age-matched controls (con-
trol 1) by staining cells with Oil Red O (ORO), a lyso-
chrome fat-soluble dye widely used for demonstrating the
presence of NL (CE and TG), which appear as bright red
spots in the cytoplasm, as described above, in Materials
and Methods. Cell mean ORO ± SE are reported in Table
1. As shown in Table 3, NL in control 1 PBMCs were gen-
erally absent (score 0) (49% female and 55% male) or
very low (score 1) (38% female and 40% male) to indicate
that intracellular lipids in the elderly are maintained at
low levels, possibly by a cyclic process, as originally
reported by Goldstein and Brown [18]. By contrast, NL
concentration in AD cells was high, since the majority of
AD-PBMCs (about 70% female and 81% male) presented
ORO staining levels with a score from 2 to 4. The intensity
of ORO staining in PBMCs positively and significantly
correlated with the severity of the cognitive alteration, as
determined by the MMSE scores in the AD population (r
= -0.419; P = 0.000) (Figure 1). No significant correlation
between MMSE and ORO staining was found in control 1
(r = 0.105; P = 0.435).
Table 2: Characteristics of control 2 and Alzheimer's disease-First-degree relatives subjects.
Control 2 AD-FDR
Total Female Male Total Female Male
N u m b e r 1 1 3 3 08 39 16 62 5
Age (mean ± SE) 44.7 ± 0.9 42.2 ± 1.7 45.6 ± 1.1 46.6 ± 1.4 45.5 ± 1.4 47.3 ± 2.6
t-test (C2 vs. AD-FDR) P = 0.229 P = 0.174 P = 0.480
ORO (mean ± SE) 0.5 ± 0.1 0.7 ± 0.1 0.4 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.2
t-test (C2 vs. AD-FDR) P = 0.000 P = 0.027 P = 0.000
AD-FDR = Alzheimer's Disease - First Degree Relatives
ORO = Oil Red OBMC Medicine 2009, 7:66 http://www.biomedcentral.com/1741-7015/7/66
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Lipid profiles in PHA-stimulated PBMCs of control 1 
subjects and AD patients
In previous studies we demonstrated that, in normal PHA-
stimulated PBMCs, CE synthesis increases at least 12
hours before the start of DNA synthesis, indicating that
cholesterol esterification is involved in the regulation of
cell-cycle progression in these cells [19-22]. In the current
study we quantified DNA synthesis and NL in PHA-stim-
ulated control 1 and AD PBMCs. DNA synthesis was
measured by 3H-thymidine incorporation in the two cell
groups cultured in parallel under identical conditions. In
PHA-stimulated control 1 cells, DNA synthesis increased
at 48 h of culture, reached a peak at 72 h and then
declined. In AD PBMCs, increased incorporation of thy-
midine into DNA was already detected 24 h after PHA
addition, reaching a peak at 48 h, indicating that PBMCs
freshly isolated from AD patients grow at a faster rate than
those from control 1 (data not shown).
Changes in 3H-thymidine incorporation were associated
with parallel changes in the content of NL. Figure 2A
shows ORO images of PHA-stimulated PBMCs from one
AD patient (85 years old) and one control 1 (84 years
old), representing 20 AD and 20 control 1, respectively. In
AD PBMCs, ORO staining was even evident at 0 h, and
steadily increased at 48-72 h. Conversely, control 1 cells
became ORO-positive at 48 h after PHA stimulation, and
still were increasing at 72 h (Figure 2B). Also of interest is
that cluster formation in AD PBMCs, indicative of cell
activation, is even evident before PHA-stimulation (0 h),
while it became manifest in control 1 only at 48 h after
stimulation.
Plasma lipid profile in control 1 subjects and AD patients
We next measured TC and HDL-C levels in plasma col-
lected from each blood sample after PBMCs separation. As
shown in Figure 3, the levels of HDL-C in AD patients
were significantly reduced, in both absolute and relative
(% HDL-C/TC) terms. TC was moderately lower in AD
patients as compared to subjects of control 1, but this was
not statistically significant. Statistical analysis revealed
that ORO staining levels negatively correlated with HDL-
C levels in AD patients (r = -0.378; P = 0.000), but not in
control 1 (Figures 4A and 4B). No significant correlation
was found between plasma TC and MMSE in AD patients
as well as in control 1 (Figure 4C). Additionally, Western
blotting with DM10 antibody, used to monitor ACAT-1
protein, revealed that ACAT-1 protein content, in ex vivo
MMSE vs ORO intensity in PBMCs from control 1 and AD Figure 1
MMSE vs ORO intensity in PBMCs from control 1 and AD. Pearson correlation test revealed a significant inverse cor-
relation between these variables in AD patients but not in control 1.
Table 3: Distribution of ORO grading in control 1 subjects and 
Alzheimer's disease patients.
Score Control 1 AD
Total Female Male Total Female Male
02 9 1 8 1 1 11 0
12 2 1 4 8 1 3 8 5
2 6 5 1 21 14 7
3 0 0 0 41 32 9
4 0 0 0 17 12 5
t o t a l 5 73 7 2 0 9 36 7 2 6
ORO = Oil Red O
AD = Alzheimer's DiseaseBMC Medicine 2009, 7:66 http://www.biomedcentral.com/1741-7015/7/66
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PBMCs was significantly greater in AD compared to con-
trol 1 (Figures 5A and 5B).
Cellular cholesterol metabolism and efflux
Given the role of HDL in preventing cell damage by
removing excess cholesterol from cells, it is conceivable
that low HDL-C level in AD patients is indicative of
decreased removal of lipids, mainly cholesterol, from tis-
sues. To verify this possibility we therefore quantified FC,
CE and TG syntheses, as well as lipid efflux, in PBMCs
from twenty subjects, four for each ORO score group (0-
4), chosen at random from the enrolled AD patients and
control 1 subjects. Total lipid synthesis (TLS) and efflux
values were obtained from the sum of [14C]acetate incor-
porated into FC, CE and TG fractions separated by TLC, in
cells and medium. As shown in Figure 6A, TLS was slightly
higher in cells with 2-4 ORO score compared to cells with
0-1 score at all time points assessed. We also noted i) a
moderate but not significant rise in FC incorporation
(data not shown) in cells with 2-4 ORO score, ii) a statis-
tically significant rise in TG, and iii) highly significant
increases in CE incorporation (Figure 6B). The fractional
rate of lipid efflux (% of [14C]lipid in medium/total
[14C]lipid) was significantly lower in 1-4 scores compared
to 0 score, at all time points (Figure 6C).
Lipid profiles in plasma and PBMCs of control 2 subjects 
and AD-FDR
It is well known that individuals who have had a late-
onset AD case in their family may run an increased risk of
developing AD themselves [16,17]. Therefore, we meas-
ured TC and HDL-C levels in plasma and carried out ORO
staining in PBMCs from 91 FDR (mean age 46.6 ± 1.4; 66
female and 25 male) of the above AD patients (AD-FDR).
We then compared data with those obtained from 113
age-matched blood donors (control 2) (mean age 44.7 ±
0.9; 30 female and 83 male) (Table 2). A high degree of
variability in the ORO data and in plasma lipid analysis of
the subjects enrolled as AD-FDR was observed (Table 2
and 4). However, 44% of PBMCs from AD-FDR had ORO
staining levels scoring 2-3, as compared to only 9.7% of
PBMCs from controls 2 (Table 4).
TC and HDL-C levels did not significantly change in FDR
plasma (Figure 7). However, HDL-C levels inversely corre-
late with ORO scores, even though not significantly (data
Neutral lipid accumulation in PHA-stimulated PBMCs from  control 1 subjects and AD patients Figure 2
Neutral lipid accumulation in PHA-stimulated 
PBMCs from control 1 subjects and AD patients. 
Immediately after separation, cells were incubated with PHA 
for the time periods indicated. After harvesting, cells were 
washed, fixed by soaking in 10% formalin, stained with ORO 
for NL, and counter-stained with Mayer's hematoxylin for 
nuclei. Cells were then examined by light microscopy and 
two different fields per sample were imaged. Red ORO inten-
sity was measured in these two fields using NIH Image J soft-
ware. Panel A shows ORO staining images for one control 1 
(84 years old; ORO score 0 at 0 time) and one AD (85 years 
old; ORO score 3 at 0 time), which are representative of 
about thirty subjects for each group. Panel B shows red 
intensity expressed as mean pixels ± SE/cm2, as described in 
Materials and Methods. *P < 0.01, compared with control 1 
by Student's t test.
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Plasma lipid profile in control 1subjects and AD patients Figure 3
Plasma lipid profile in control 1subjects and AD 
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HDL-C vs ORO intensity and MMSE vs TC in PBMCs from control 1 and AD. A. HDL-C vs ORO intensity; B. %HDL-C vs  ORO intensity; C. MMSE vs TC Figure 4
HDL-C vs ORO intensity and MMSE vs TC in PBMCs from control 1 and AD. A. HDL-C vs ORO intensity; B. 
%HDL-C vs ORO intensity; C. MMSE vs TC. The test revealed a significant inverse correlation between HDL-C and 
%HDL/TC vs ORO in AD patients but not in control 1. No correlation was observed between MMSE vs TC in both groups.
BMC Medicine 2009, 7:66 http://www.biomedcentral.com/1741-7015/7/66
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not shown). Interestingly, three unaffected relatives of
comparable age (two brothers and one sister) of three AD
patients did not have relevant accumulation of neutral lip-
ids in their PBMCs, nor had lower levels of HDL-C (data
not shown). When PBMCs were stimulated with PHA,
about half the PBMCs exhibited ORO kinetics similar to
those of AD patients, while the other half were similar to
controls 2 (Figures 8A and 8B). In agreement with these
data, ACAT-1 Western blotting analysis revealed that
about 50% of ex vivo FDR PBMCs show a significant
increase in ACAT-1 protein levels compared to controls 2
(Figures 9A and 9B).
Discussion
Cholesterol is essential for the organization of liquid-
ordered microdomains (rafts) in the plasma membrane,
which serve as a scaffold for the proper assembling and
functioning of a variety of membrane-associated proteins,
including β- and γ-secretases [23,24] that are involved in
the Aβ formation. Progressive accumulation of Aβ in the
brain is considered a pathogenetic event common to all
forms of AD [25]. This suggests that alterations in choles-
terol homeostasis and, more specifically, in raft organiza-
tion may also have a great influence on AD development
and progression [26-28]. In particular, CEs, rather than
FC, seem to be directly correlated with Aβ production. It
has, in fact, been reported that Aβ generation is modu-
lated by the activity of acyl-coenzyme A: cholesterol acyl-
transferase (ACAT), the enzyme that catalyses the
formation of CEs inside cells [29,30]. Inhibitors of ACAT
were reported to strongly reduce Aβ production in cell and
AD animal-based models [31,32]. In depth, it was
reported that in a mouse model of AD the ACAT inhibitor
CP-113,818 reduced by 90% amyloid pathology as com-
pared to transgenic mice which received placebo [32].
Findings reported here show significantly higher neutral
lipid levels (mainly CE) and increased ACAT-1 protein
amounts in at least 85% of PBMCs freshly isolated (ex
vivo) from patients with probable sporadic AD as com-
pared to cognitively normal age-matched controls. These
data are in keeping with and extend our preliminary find-
ings showing higher NL levels in AD PBMCs [33], and fur-
ther support the hypothesis that intracellular CE levels are
systemically increased in AD-patients. That said, at least in
theory, one might expect that cholesterol levels in the
plasma HDL fraction, which is responsible for removing
the excess of cholesterol from cells, will undergo a
decrease [34]. In accordance with this, a recent study of
middle-aged adults reports a link between low HDL-C
and memory loss. Decreasing HDL-C was associated with
memory decline over a five-year follow-up period; while
no link was found between TC and TG plasma concentra-
tions and memory deficit or decline [35]. Similarly, we
found a significant reduction, both in absolute and rela-
tive terms, in HDL-C levels in plasma from AD blood sam-
ples as compared to age-matched controls. A moderate
reduction in TC was also observed by us in AD patients.
Additionally, correlation analyses revealed a positive cor-
relation between HDL-C and MMSE, as well as between
HDL-C and CE accumulation, as determined by ORO
staining in AD patients. Although the significance, if any,
of the observed correlation between low HDL-C levels
and AD risk remains to be established, our data indicate
that the low HDL-C levels in the plasma of AD patients
may be a consequence of a decreased removal rate of cho-
lesterol from tissues, as a result of the increased entrap-
ment of CEs by cells. In reality, the fractional rate of lipid
efflux (% of 14C-lipid in medium/total14C-lipid) was sig-
nificantly lower in those cells with high ORO scores com-
pared to those with low scores. It therefore seems that low
HDL-C levels, coupled with lipid accumulation in periph-
eral cells, represent an additional index of AD. Interest-
ingly, no correlation was found between total plasma
cholesterol and MMSE in AD patients, indicating that,
contrary to what has been reported in several other stud-
ies, hypercholesterolemia per se does not appear to be a
risk factor for AD [36-38].
ACAT-1 protein expression in control 1 and AD PBMCs Figure 5
ACAT-1 protein expression in control 1 and AD 
PBMCs. Western blotting with DM10 was used to monitor 
ACAT-1 protein content. The anti-ACAT-1 DM10 antibody 
specifically recognized a single protein band from PBMC 
extracts with an apparent molecular weight of about 50 kDa. 
No other protein signal(s) was detectable. A. Representative 
ACAT-1 immunoblot. B. Results of densitometric analysis by 
Scion Image software of ACAT-1 protein immunoreactivity 
relative to β-actin in 20 AD patients and 20 control 1. Data 
values are represented as mean ± SE *P = 0.000 vs control 1.
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Lipid synthesis and efflux in PBMCs with different ORO scores Figure 6
Lipid synthesis and efflux in PBMCs with different ORO scores. Freshly isolated PBMCs (four for each ORO score 
group) were plated at a density of 10,000 cell/cm2 in six well plates and incubated with PHA for the time periods indicated. 
Total cellular lipid synthesis (A) and cholesterol ester synthesis (B) were evaluated by incubating cells for six hours in medium 
containing [14C]acetate at a final concentration of 2 μCi/ml. After incubation, cells were washed with PBS and lipids extracted 
with acetone. Lipid subclasses were separated out by thin layer chromatography (TLC) and [14C]acetate incorporation into the 
various lipid fractions was measured. Efflux (C) from the cells into the medium at each time point was expressed as the per-
centage of radioactivity in medium/total radioactivity (cells + medium). Data shown are the mean ± SE of four subjects from 
each score group, *P < 0.05.
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However, although it is generally accepted that alterations
in cholesterol metabolism are a critical event in AD, it is
still unclear whether they are the cause or the effect of dis-
ease and, actually, we cannot completely exclude the pos-
sibility that changes in lipid metabolism may be due to
factors other than AD. Dementia occurs late in life, but it
is increasingly recognized that there is a long preclinical
phase characterized by progressive neuropathological
changes that become clinically detectable with age. The
"life-long" view of dementia contributes to stress the
importance of risk factors in midlife [39]. Individuals who
have had a late-onset AD case in their family may run an
increased risk of developing AD themselves [17,18], thus
the analysis of lipid metabolism in these subjects could be
a suitable biochemical approach to monitor changes in
cholesterol homeostasis before any cognitive decline
might occur. We observed great variability in the ORO
data and in plasma lipid analysis of the subjects enrolled
as AD-FDR. However, 44% of PBMCs from AD-FDR had
ORO staining levels that scored from 2 to 3, as compared
to only 9.7% of PBMCs from controls.
Conclusion
Overall, the assessment of cholesterol ester metabolism in
PBMCs ex vivo by means of a reliable assay that can be
easily and quickly performed might be a very useful bio-
chemical tool in support to AD diagnosis. In addition, the
fact that some AD-FDR tend to display a metabolic choles-
terol pattern similar to that of AD patients, may suggest
that the determination of PBMC ORO staining and
plasma HDL-C levels may be useful for identification of a
subset of midlife subjects who might run a major risk of
developing AD; and the identification of incipient AD-
related cognitive impairment would be the basis for initi-
ation of treatment with drugs that might slow or stop the
degenerative process, such as ACAT inhibitors [29-31].
Above all it remains to be assessed whether: i) changes in
NL are also present in PBMCs from patients with non-AD
neuropathologies such as for instance vascular, Lewy body
and frontotemporal dementias; ii) asymptomatic individ-
uals with decreased plasma HDL-C and increased PBMC
lipids will really go on towards Alzheimer's disease over
time.
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Plasma lipid profile in control 2 and AD-FDR Figure 7
Plasma lipid profile in control 2 and AD-FDR. Data are 
expressed as a mean ± SE of the enrolled subjects. *TC P = 
0.784; HDL P = 0.154; %HDL/TC P = 0.04; TC female P = 
0.185; D HDL female P = 0.304; % HDLC/TC female P = 0.05; 
TC male P = 0.490; HDL male P = 0.215; %HDLC/TC male, P 
= 0.316 of AD-FDR vs the corresponding control 2 by Stu-
dent's t test.
TC HDL-C HDL-C/TC -- TC HDL-C HDL-C/TC-- TC HDL-C HDL-C/TC
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ACAT-1 protein expression in PBMCs from control 2 and  AD-FDR subjects Figure 9
ACAT-1 protein expression in PBMCs from control 2 
and AD-FDR subjects. Western blotting with DM10 was 
used to monitor the ACAT-1 protein content. The anti-
ACAT-1 DM10 antibody specifically recognized a single pro-
tein band from cell extracts of PBMCs, with an apparent 
molecular weight of 50 kDa. No other protein signal(s) was 
detectable. A. Representative immunoblot of ACAT-1 of two 
control 2; two AD-FDR with ORO score between 0 and 1 
(FDR-1) and two AD-FDR with ORO score between 2-3 
(FDR-2). B. Results of densitometric analysis by Scion Image 
software of ACAT-1 protein.
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